title: Effectiveness of Imatinib Mesylate Treatment in a Patient with Dermatofibrosarcoma Protuberans with Pulmonary and Pancreatic Metastases.
abstract: We herein encountered a case of abdominal wall dermatofibrosarcoma protuberans (DFSP) that developed pulmonary and pancreatic metastases 5 years after complete resection. Because specific rearrangements of the platelet-derived growth factor beta (PDGFB) locus by a novel fluorescence in situ hybridization method was detected, the patient was treated with imatinib mesylate at 400 mg/day. A partial response was achieved by imatinib without any specific toxicity. Although metastatic DFSP is an extremely rare disease, an evaluation of PDGFB fusion is essential and imatinib mesylate should be considered as an optimal therapeutic choice in patients with metastatic or locally advanced DFSP.
authors: Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Japan.
authors: Toshiharu
authors: T
authors: Tatai
authors: Daisuke
authors: D
authors: Gomi
authors: Toshirou
authors: T
authors: Fukushima
authors: Takashi
authors: T
authors: Kobayashi
authors: Nodoka
authors: N
authors: Sekiguchi
authors: Akiyuki
authors: A
authors: Sakamoto
authors: Shigeru
authors: S
authors: Sasaki
authors: Tomonobu
authors: T
authors: Koizumi
authors: Kenji
authors: K
authors: Sano
mesh_terms: D000005:Abdomen; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018223:Dermatofibrosarcoma / Q000473:pathology* / Q000601:surgery; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D017404:In Situ Hybridization, Fluorescence; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000556:secondary*; D010982:Platelet-Derived Growth Factor; D012878:Skin Neoplasms / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents; D010982:Platelet-Derived Growth Factor; D000068877:Imatinib Mesylate